lovastatin has been researched along with Cerebrovascular Disorders in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 8 (80.00) | 18.2507 |
| 2000's | 1 (10.00) | 29.6817 |
| 2010's | 1 (10.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Arca, M; Budal, S; Degli Esposti, E; Degli Esposti, L; Sangiorgi, D; Vigna, GB | 1 |
| Bozhko, GKh; Chursina, VS; Pertseva, TG; Sokolik, VV | 1 |
| Boop, BS; Hart, RG; Sherman, DG | 1 |
| Cooper, ME; Gilbert, RE; Jerums, G | 1 |
| Gotto, AM | 1 |
| Byington, RP; Crouse, JR; Furberg, CD; Hoen, HM | 1 |
| Evans, MF; Por, CP; Sabharwal, M | 1 |
| Ballantyne, CM; Jacobson, TA; Schein, JR; Williamson, A | 1 |
| Echeandia, C; Figuerola, A; Marta-Moreno, J; Mola, S; Oliveros-Cid, A | 1 |
3 review(s) available for lovastatin and Cerebrovascular Disorders
| Article | Year |
|---|---|
Reductase inhibitor monotherapy and stroke prevention.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Cerebrovascular Disorders; Coronary Disease; Female; Humans; Hydroxymethylglutaryl CoA Reductases; Incidence; Lovastatin; Male; Middle Aged; Pravastatin; Simvastatin; Treatment Outcome | 1997 |
Maximizing the cost-effectiveness of lipid-lowering therapy.
Topics: Anticholesteremic Agents; Atorvastatin; Carotid Stenosis; Cerebrovascular Disorders; Clinical Trials as Topic; Coronary Disease; Cost-Benefit Analysis; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Pravastatin; Pyrroles; Simvastatin | 1998 |
[Statins (HMG-CoA reductase inhibitors), cholesterol and stroke].
Topics: Adult; Arteriosclerosis; Cerebrovascular Disorders; Cholesterol; Clinical Trials as Topic; Drug Evaluation; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Ischemic Attack, Transient; Lipoproteins, HDL; Lipoproteins, LDL; Lovastatin; Male; Middle Aged; Pravastatin; Risk Factors; Simvastatin; Triglycerides | 1998 |
7 other study(ies) available for lovastatin and Cerebrovascular Disorders
| Article | Year |
|---|---|
[Achievement of therapeutic target in subjects on statin treatment in clinical practice. Results of the STAR (Statins Target Assessment in Real practice) study].
Topics: Aged; Algorithms; Azetidines; Biomarkers; Cardiovascular Diseases; Cerebrovascular Disorders; Cholesterol, LDL; Cohort Studies; Diabetes Complications; Diabetes Mellitus; Ezetimibe; Female; Fluorobenzenes; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Italy; Lovastatin; Male; Medication Adherence; Middle Aged; Pravastatin; Pyrimidines; Retrospective Studies; Risk Assessment; Risk Factors; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome | 2011 |
[A short-term effect of lovastatin on lipoprotein metabolism in patients with cerebrovascular lesions concomitant with diabetes mellitus II type].
Topics: Biomarkers; Cerebrovascular Disorders; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins; Lovastatin; Male; Middle Aged; Time Factors; Treatment Outcome | 2006 |
Cholesterol lowering and the risk of stroke.
Topics: Anticholesteremic Agents; Cerebrovascular Disorders; Clinical Trials as Topic; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Risk; Simvastatin | 1996 |
Primary prevention of stroke.
Topics: Acyl Coenzyme A; Anticholesteremic Agents; Arteriosclerosis; Cerebrovascular Disorders; Controlled Clinical Trials as Topic; Enzyme Inhibitors; Humans; Hypercholesterolemia; Lovastatin; Meta-Analysis as Topic; Oxidoreductases; Pravastatin; Simvastatin | 1996 |
Stain therapy and reduced incidence of stroke. Implications of cholesterol-lowering therapy for cerebrovascular disease.
Topics: Anticholesteremic Agents; Cerebrovascular Disorders; Clinical Trials as Topic; Coronary Disease; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Lovastatin; Simvastatin | 1997 |
HMG-CoA reductase inhibitors reduce stroke risk, total mortality.
Topics: Cerebrovascular Disorders; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lovastatin; Meta-Analysis as Topic; Mortality; Pravastatin; Simvastatin | 1997 |
Do statin drugs lower the risk of stroke?
Topics: Anticholesteremic Agents; Cerebrovascular Disorders; Coronary Disease; Humans; Lovastatin; Meta-Analysis as Topic; Pravastatin; Risk Factors; Simvastatin | 1998 |